VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | Progression patterns in post-ipilimumab and anti-PD-1 in metastatic melanoma

Ines Pires Da Silva, MD, PhD, Melanoma Institute Australia, Sydney, New South Wales, Australia & The University of Sydney Central Clinical School, Sydney, New South Wales, Australia, provides an overview of various progression patterns in patients with metastatic melanoma after receiving first-line ipilimumab combined with anti-PD-1 treatment. In a group of 301 patients, patterns of progression were categorized as innate progression, acquired resistance, or pseudoprogression. Management and outcomes of different types of progression were additionally discussed, with BRAF/MEK inhibitors improving overall survival (OS) and chemotherapy having no effect on OS. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Ines Pires Da Silva, MD, PhD has received speaker fees and travel support from BMS, MSD and Roche.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter